Skip to main content

Table 3 Summary of recent developments in ATD administration and long term outcome

From: How to use thionamide anti-thyroid drug in the young– what’s new?

• PTU should be avoided in the young patient with thyroid hormone excess.
• Long term ATD therapy with CBZ or MMI in excess of 3 years duration is a realistic option for young patients with GD who are at high risk of relapse.
• Data from a randomised trial indicates that DT ATD therapy is associated with similar biochemical control when compared to BR.
• Weight gain can be a major problem in patients with GD starting ATD treatment. This should be discussed with the young person and their family at an early stage.
• Patients in remission following ATD need monitoring because of the potential for autoimmune hypothyroidism as well as relapse.